Unilateral Versus Bilateral Endoscopic Resection of Olfactory Neuroblastoma: Pooled Analysis From Prospective and Retrospective Multicenter Data

• DOI: 10.1002/alr.23531
• Publication Date: 2025-01-15T09:38:32Z
• Authors: Arash Abiri; Theodore V. Nguyen; Haidee Chen; Elise Krippaehne; David K. Lerner; Arifeen S. Rahman; Pooya Roozdar; Brandon R. Rosvall; Michael Sabbaj; Alan D. Workman; Shannon Wu; Nithin D. Adappa; Daniel M. Beswick; Eugene H. Chang; Michael T. Chang; Garret Choby; Jacob G. Eide; Jennifer E. Douglas; Mathew Geltzeiler; Michael A. Kohanski; Peter H. Hwang; Christopher H. Le; Jivianne T. Lee; Jayakar V. Nayak; James N. Palmer; Zara M. Patel; Carlos D. Pinheir...; Adam C. Resnick; Timothy L. Smith; Carl H. Snyderman; Maie A. St John; Phillip B. Storm; Jeffrey D. Suh; Marilene B. Wang; Eric W. Wang; Edward C. Kuan
• Keywords: Esthesioneuroblastoma

Olfactory neuroblastoma (ONB) is a rare sinonasal malignancy primarily treated with surgery. For tumors arising from the olfactory area, traditional treatment involves transcribriform resection of anterior cranial fossa. Surgery can be performed unilateral or bilateral depending on extent involvement; however, there are currently no studies comparing outcomes between two. Prospective and retrospective data primary ONB patients were collected multicenter registry involving eight academic sites. Propensity score matching (PSM) was used to create patient cohorts similar baseline characteristics. Cox proportional hazards Kaplan Meier analyses assessed overall survival (OS). Logistic regression associations (unilateral versus bilateral) tumor recurrence postoperative cerebrospinal fluid (CSF) leak. A total 187 (47.6% female) an average age 53.6 ± 15.1 years analyzed. Most (81.3%) predominantly Kadish C (58.3%) Hyams II (55.8%). Overall, 56.7% underwent resection. Fifty-four experienced nine had CSF leaks. Following PSM (n = 45/group), not associated mortality (hazard ratio [HR] 1.73; p 0.407) OS (p 0.400). There association (odds [OR] 0.90; 0.814) leak (OR 1.54; 0.647). where may feasible oncologically sound, decision for showed significant effect survival, recurrence, Oncologic comparable when tailored individual